Krystal Biotech, Inc. - Common Stock (KRYS)

Competitors to Krystal Biotech, Inc. - Common Stock (KRYS)

Amgen Inc. 

Amgen and Krystal Biotech are both involved in developing innovative therapies aimed at treating genetic and rare diseases. While Krystal Biotech focuses on gene therapy through its proprietary platform, Amgen has a broader portfolio with established therapies and a larger scale for development and commercialization. In this competitive landscape, Amgen's extensive resources and experience provide it with a competitive advantage, especially in terms of funding and clinical trial capabilities.

Audentes Therapeutics, Inc.

Audentes Therapeutics is another player in the field of gene therapy, focusing on treating rare genetic diseases through AAV-mediated gene delivery. Both companies share the challenge of providing innovative solutions for patients with genetic disorders, yet they differ in their approach and specific therapies under development. Audentes has an established pipeline and partnerships which can enhance its competitive stature, thereby making them a significant rival to Krystal Biotech, whose specialized approach may be at a developmental stage relative to Audentes’ broader clinical efforts.

Bluebird Bio, Inc. 

Bluebird Bio and Krystal Biotech operate in the investigational gene therapy landscape, addressing genetic diseases with potentially life-altering treatments. Bluebird's focus on integrating gene therapy with cellular therapies offers unique solutions compared to Krystal Biotech's focus on topical gene delivery. Despite having innovative products, Bluebird's extensive clinical experience and its existing partnerships give it a competitive edge in navigating regulatory pathways and market entry, placing it ahead in terms of resource availability and expertise.

Sangamo Therapeutics, Inc. 

Sangamo Therapeutics and Krystal Biotech compete in the gene therapy space, each utilizing unique technologies to address genetic diseases. Sangamo's work primarily revolves around gene editing and engineered cell therapies, giving them a distinct approach compared to Krystal's focus on delivering corrective genes through its skin or tissue-targeted delivery system. Despite having a different technological focus, both companies target similar therapeutic areas, leading to strong competition; however, Krystal's specialized delivery methods may serve as a competitive edge in certain applications.